Yen‐Ling Chiu

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

New advances in CMV and immunosenescence

Paolo Sansoni, Rosanna Vescovini, Francesco Fagnoni et al. · Experimental Gerontology · 2014 · 147 citations · Full text

Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy

Karlo Perica, Joan Glick Bieler, Christian Schütz et al. · ACS Nano · 2015 · 144 citations · Full text

Engineering, Immunology, Biomedical Engineering +19

Nanoscale artificial antigen presenting cells for T cell immunotherapy

Karlo Perica, Andrés De León Medero, Malarvizhi Durai et al. · Nanomedicine Nanotechnology Biology and Medicine · 2013 · 135 citations · Full text

Nanomedicine, Immunology, Therapeutic Vaccine +6